Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Diseases and Illnesses
  5. Covid 19

Covid-19

Thumbnail
March 28, 2023

Profitability and pipeline in focus at post-pandemic Biontech

Thumbnail
February 28, 2023

Go or no go? Vaccines and neurology up for discussion

FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.

Evaluate

Thumbnail
March 28, 2023

Profitability and pipeline in focus at post-pandemic Biontech

Thumbnail
February 28, 2023

Go or no go? Vaccines and neurology up for discussion

FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.

Article image
Vantage logo
June 27, 2022

Covid vaccine development could go Omicron-and-on

Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?

Article image
Vantage logo
June 16, 2022

Testing times for Roche despite new Covid assay

Article image
Vantage logo
June 09, 2022

Novavax and Moderna continue the fight for Covid relevance

Article image
Vantage logo
June 01, 2022

US FDA approval tracker: May 2022

Article image
Vantage logo
May 31, 2022

Go or no go? The FDA’s Amylyx dilemma

June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.

Article image
Vantage logo
May 30, 2022

Move over Humira, it's the cancer antibodies' turn at the top

Article image
Vantage logo
May 24, 2022

The Covid vaccine battleground gets younger

The FDA has finally confirmed the date of a review of Covid vaccine data in the very young, but has Pfizer/Biontech already won the race?

Article image
Vantage logo
May 16, 2022

Valneva and Synairgen remain Covid laggards

Article image
Vantage logo
May 09, 2022

Covid drives a record jump in research spending for big pharma

A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.

  • Load More
Article image
Vantage logo
June 27, 2022

Covid vaccine development could go Omicron-and-on

Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?

Article image
Vantage logo
June 16, 2022

Testing times for Roche despite new Covid assay

Article image
Vantage logo
June 09, 2022

Novavax and Moderna continue the fight for Covid relevance

Article image
Vantage logo
June 01, 2022

US FDA approval tracker: May 2022

Article image
Vantage logo
May 31, 2022

Go or no go? The FDA’s Amylyx dilemma

June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.

Article image
Vantage logo
May 30, 2022

Move over Humira, it's the cancer antibodies' turn at the top

Article image
Vantage logo
May 24, 2022

The Covid vaccine battleground gets younger

The FDA has finally confirmed the date of a review of Covid vaccine data in the very young, but has Pfizer/Biontech already won the race?

Article image
Vantage logo
May 16, 2022

Valneva and Synairgen remain Covid laggards

Article image
Vantage logo
May 09, 2022

Covid drives a record jump in research spending for big pharma

A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up